Medical Patent News RSS Feed - Medical Patent News

Actavis files ANDA with FDA to market  Colchicine Tablets USP

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. [More]
Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer issues 5 new patents directed to Subchondroplasty Procedure

Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today announced that the United States Patent and Trademark Office has issued five new patents directed to the Subchondroplasty® Procedure, the innovative new joint preservation procedure developed by Zimmer Knee Creations: U.S. Patent No. 8,551,178, U.S. Patent No. 8,574,303, U.S. Patent No. 8,608,802, U.S. Patent No. 8,617,166 and U.S. Patent No. 8,623,089. [More]
New drug patent may help overcome problems associated with MDR-TB

New drug patent may help overcome problems associated with MDR-TB

A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics. [More]
Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery." [More]
NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth. [More]
New patent allows 22 claims surrounding Reverse Medical’s "MVP" technology platform

New patent allows 22 claims surrounding Reverse Medical’s "MVP" technology platform

Reverse Medical Corporation announced today that the United States Patent Office has notified the Company that a new patent has issued entitled "Embolic Implant and Method of Use". [More]
Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms. [More]

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). [More]
Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

​A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury. [More]
Impact Sports Technologies receives 18th patent for mobile optical heart rate monitoring technology

Impact Sports Technologies receives 18th patent for mobile optical heart rate monitoring technology

Impact Sports Technologies, Inc., the industry leader in innovative motion resistant strapless heart rate applications, has received its 18th patent, featuring the use of its mobile optical heart rate monitoring technology with a mobile communications device. [More]
Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. [More]
Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. [More]
Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

Professor wins U.S. Patent for use of antioxidant compound used in treatment of obesity

A Skidmore College alumnus and professor have been awarded U.S. Patent No. 8,598,150 for use of an antioxidant compound that shows promise in the treatment of obesity and related disorders, such as type-2 diabetes. [More]

USPTO rejects NIKKEN's effort to invalidate Imagenetix's patent

Imagenetix, Inc. (OTC Bulletin Board: IAGXQ), announced today that the Board of Appeals for the United States Patent & Trade Office (USPTO) rejected NIKKEN's effort to invalidate Imagenetix's patent no. 5,569,676 and issued a decision confirming the validity of the patent. [More]
GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma. [More]
NSU scientist awarded U.S. patent to develop fall prevention model

NSU scientist awarded U.S. patent to develop fall prevention model

Each year, one in every three adults age 65 and older falls, according to the Centers for Disease Control (CDC). These falls are the leading cause of fatal and nonfatal injuries among older adults, resulting in approximately $30 billion in direct medical costs per year. [More]
USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery. [More]
Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes. [More]
European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

22nd Century Group, Inc. today announced that the European Patent Office issued a Notice of Grant to the company for the NBB and A622 genes. Both genes are responsible for nicotine production in the tobacco plant. [More]
Neovasc's Tiara transcatheter mitral valve replacement technology gets US patent

Neovasc's Tiara transcatheter mitral valve replacement technology gets US patent

Neovasc Inc. today announced that the first patent covering the company's innovative Tiara transcatheter mitral valve replacement technology has been issued by the US Patent and Trademark Office. [More]